News & Updates
Filter by Specialty:
Bright light therapy of no benefit in teens with moderate or severe depression
In the treatment of adolescents with moderate or severe major depressive disorder, adding bright light therapy to psychiatric inpatient treatment as usual falls short of significantly reducing depressive symptoms when compared with placebo, as shown in a study.
Bright light therapy of no benefit in teens with moderate or severe depression
19 Mar 2024Stopping TDF prophylaxis immediately postpartum feasible in highly viraemic CHB mothers
In highly viraemic pregnant women with chronic hepatitis B (CHB), stopping peripartum prophylaxis (PP) with tenofovir disoproxil fumarate (TDF) immediately after delivery does not increase the risk of relapse or retreatment vs TDF cessation at ≥4 weeks postpartum. Early withdrawal of PP-TDF, combined with standard neonatal immunization schemes, is 100 percent effective in preventing mother-to-child transmission (MTCT).
Stopping TDF prophylaxis immediately postpartum feasible in highly viraemic CHB mothers
19 Mar 2024Bloodstream infection tied to ICU admission, death in children hospitalized for flu
Bloodstream infections rarely occur in children hospitalized for influenza but are associated with intensive care unit (ICU) admission, mechanical ventilation, longer hospital stay, and higher in-hospital mortality, according to a study.
Bloodstream infection tied to ICU admission, death in children hospitalized for flu
18 Mar 2024Trifarotene clears acne battle scars
Individuals dealing with the stubborn scars and hyperpigmentation left behind by acne may find benefit in trifarotene cream – the newest among the new generation of topical retinoids approved for acne treatment, according to the findings of two vehicle-controlled, phase IV studies presented at AAD 2024.
Trifarotene clears acne battle scars
18 Mar 2024Water-free cyclosporine eye drops a promising treatment for dry eye disease
Individuals with moderate-to-severe dry eye disease appear to obtain marked symptomatic improvements with a water-free cyclosporine 0.1% eye solution, according to the results of a phase III vehicle-controlled study from China.